BeOne Medicines (NASDAQ:ONC) CFO Aaron Rosenberg Sells 1,157 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CFO Aaron Rosenberg sold 1,157 shares of BeOne Medicines stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $312.71, for a total value of $361,805.47. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Aaron Rosenberg also recently made the following trade(s):

• On Thursday, June 11th, Aaron Rosenberg sold 631 shares of BeOne Medicines stock. The stock was sold at an average price of $257.74, for a total value of $162,633.94.

BeOne Medicines Price Performance

ONC traded up $4.52 during trading on Wednesday, reaching $327.53. 476,546 shares of the company traded hands, compared to its average volume of 280,740. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $253.95 and a 12-month high of $385.22. The firm has a fifty day simple moving average of $293.98 and a 200 day simple moving average of $308.75. The company has a market cap of $35.94 billion, a P/E ratio of 73.27 and a beta of 0.49.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.40 by $0.65. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. On average, equities analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 5.93 EPS for the current year.

BeOne Medicines News Summary

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Q2 earnings surpassed expectations: BeOne Medicines reported adjusted earnings of $2.05 per share, well above the $1.40 analyst consensus. The result strengthens the investment case by demonstrating better-than-expected profitability. BeOne Medicines Q2 earnings report
• Positive Sentiment: Revenue outlook exceeded forecasts: Management projected fiscal 2026 revenue of $6.6 billion to $6.8 billion, compared with Wall Street’s $6.5 billion expectation. The guidance suggests continued momentum across the company’s oncology portfolio. BeOne Medicines Q2 metrics
• Positive Sentiment: Pipeline progress provided additional support: BeOne’s liver-cancer bispecific received a UK Innovation Passport, potentially helping accelerate development and regulatory engagement for the candidate. BeOne lands UK Innovation Passport
• Neutral Sentiment: Analyst sentiment remains favorable: Recent coverage maintained predominantly Buy or Overweight ratings, with a reported consensus price target of approximately $394, although the stock’s elevated valuation leaves expectations high.
• Neutral Sentiment: Insider transactions were sales for tax purposes: CFO Aaron Rosenberg sold 1,157 shares worth about $362,000, while SVP Chan Henry Lee sold 1,044 shares worth approximately $338,000. Both transactions were explicitly tied to tax withholding on vested equity awards, reducing their significance as a bearish signal. BeOne CFO SEC filing

Hedge Funds Weigh In On BeOne Medicines

Large investors have recently made changes to their positions in the company. Bank of America Corp DE bought a new position in BeOne Medicines during the 2nd quarter valued at about $67,657,000. Man Group plc bought a new stake in BeOne Medicines in the second quarter worth about $59,031,000. BNP Paribas Financial Markets purchased a new position in shares of BeOne Medicines during the second quarter valued at approximately $38,337,000. First Trust Advisors LP boosted its position in shares of BeOne Medicines by 91.9% during the first quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock valued at $71,696,000 after buying an additional 115,601 shares during the period. Finally, Qube Research & Technologies Ltd bought a new position in shares of BeOne Medicines during the second quarter valued at approximately $26,034,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 18th. Zacks Research lowered BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 3rd. Leerink Partners raised their price target on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a report on Friday, May 15th. Morgan Stanley reaffirmed an “overweight” rating and issued a $395.00 price objective on shares of BeOne Medicines in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada upped their price objective on BeOne Medicines from $436.00 to $451.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, BeOne Medicines currently has a consensus rating of “Moderate Buy” and an average price target of $394.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.